The therapeutic potential of small molecule TACE inhibitors

Bibliography

• AGGARWAL BB, KOHR WJ, HASS PE et al: Human tumor necrosis factor production, purification, and charac-terization. J. Biol. Chem. (1985) 260 (4) :2345–2354.
   PubMed Web of Science ®Google Scholar
• TRACEY KJ, CERAMI A: Tumor necrosis factor: a pleio-tropic cytokine and therapeutic target. Ann. Rev. Med. (1994) 45:491–503.
   PubMed Web of Science ®Google Scholar
• •Review of the physiological effects of TNF.
   Google Scholar
• AGGARWAL BB, NATARAJAN K: Tumor necrosis factors: developments during the last decade. Euro. Cytokine Net. (1996) 7(2):93–124.
   PubMed Web of Science ®Google Scholar
• •Review of the physiological effects of TNF.
   Google Scholar
• BEMELMANS MH, VAN TITS LJ, BUURMAN WA: Tumor ne- crosis factor: function, release and clearance. Grit. Rev. Immunol. (1996) 16(0:1–11.
   PubMedGoogle Scholar
• •Review of the physiological effects of TNF.
   Google Scholar
• DE TOGNI P, GOELLNER J, RUDDLE NH et al: Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science (1994) 264:703–707.
   PubMed Web of Science ®Google Scholar
• LOWE C: Tumour necrosis factor-a antagonists and their therapeutic applications. Exp. Opin. Ther. Patents (1998) 8(10):1309–1322.
   Web of Science ®Google Scholar
• •Overview of the different classes of TNF-a inhibitors.
   Google Scholar
• SHIRE MG, MULLER GW: TNF-a inhibitors and rheuma- toid arthritis. Exp. Opin. Ther. Patents (1998) 8(5) :531–544.
   Web of Science ®Google Scholar
• •Overview of the different classes of TNF-a inhibitors.
   Google Scholar
• CAMUSSI G, LUPIA E: The future role of anti-tumour ne- crosis factor (TNF) products in the treatment of rheu-matoid arthritis. Drugs (1998) 55 (5):613–620.
   PubMed Web of Science ®Google Scholar
• •Overview of the different classes of TNF-a inhibitors.
   Google Scholar
• BLACK RA, BIRD TA, MOHLER KM: Agents that block TNF-a synthesis or activity. Ann. Rep. Medic. Chem. (1997) 32:241–250.
   Web of Science ®Google Scholar
• •Overview of the different classes of TNF-a inhibitors.
   Google Scholar
• EIGLER A, SINHA B, HARTMANN G, ENDRES S: Taming TNF: strategies to restrain this proinflammatory cyto-kine. Immunol. Today (1997) 18(10487–492.
   Google Scholar
• •Overview of the different classes of TNF-a inhibitors.
   Google Scholar
• Anti-TNF agents offer new approaches in arthritis. Scrip (November 20, 1998) 2389:24–25.
   Google Scholar
• First approval for immunex's enbrel. Scrip (November 6, 1998) 2385: 14.
   Google Scholar
• BLACK RA, RAUCH CT, KOZLOSKY CJ et al.: A metallopro-teinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature (1997) 385:729–33.
   PubMed Web of Science ®Google Scholar
• MOSS ML, JIN SL, MILLA ME et al.: Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature (1997) 385:733–736.
   PubMed Web of Science ®Google Scholar
• MOHLER KM, SLEATH PR, FITZNER JN et al: Protection against a lethal dose of endotoxin by an inhibitor of tu-mour necrosis factor processing. Nature (1994) 370:218–220.
   PubMed Web of Science ®Google Scholar
• MCGEEHAN GM, BECHERER JD, BAST RC et al: Regula-tion of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature (1994) 370:558–561.
   PubMed Web of Science ®Google Scholar
• GEARING AJ, BECKETT P, CHRISTODOULOU M et al: Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature (1994) 370:555–557.
   PubMed Web of Science ®Google Scholar
• AMOUR A, SLOCOMBE PM, WEBSTER A et al: TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. (1998) 435(0:39–44.
   PubMedGoogle Scholar
• BLACK RA, WHITE JM: ADAMs: focus on the protease do-main. Curr. Opin. Cell Biol. (1998) 10:564–659.
   Google Scholar
• ••Excellent overview of the ADAM metalloproteinase family.
   Google Scholar
• MASKOS K, FERNANDEZ-CATALAN C, HUBER R et al.: Crystal structure of the catalytic domain of human tu-mor necrosis factor-a-converting enzyme. Proc. Natl. Acad. ScL USA (1998) 95:3408–3412.
   PubMed Web of Science ®Google Scholar
• ••First report of the crystal structure of the TACE catalytic do-main. Shown with a bound inhibitor.
   Google Scholar
• GEORGOPOULOS S, PLOWS D, KOLLIAS: Transmem-brane TNF is sufficient to induce localized tissue toxic-ity and chronic inflammatory arthritis in transgenic mice. J. Inflamm. (1996) 46:86–97.
   PubMedGoogle Scholar
• PROBERT L, AKASSOGLOU K, ALEXOPOULOU L et al.: Dissection of the pathologies induced by transmem-brane and wild-type tumor necrosis factor in trans-genic mice. J. Leuk Biol. (1996) 59:518–525.
   PubMed Web of Science ®Google Scholar
• GRELL M, DOUNI E, WAJANT H et al.: The transmem-brane form of tumor necrosis factor is the prime acti-vating ligand of the 80 kDa tumor necrosis factor receptor. Cell (1995) 83 (5):793–802.
   PubMed Web of Science ®Google Scholar
• GEORGOPOULOS S, PLOWS D, KOLLIAS: Transmem-brane TNF is sufficient to induce localized tissue toxic-ity and chronic inflammatory arthritis in transgenic mice. J. Inflamm. (1996) 46:86–97.
   PubMedGoogle Scholar
• PROBERT L, AKASSOGLOU K, ALEXOPOULOU L et al.: Dissection of the pathologies induced by transmem-brane and wild-type tumor necrosis factor in trans-genic mice. J. Leuk Biol. (1996) 59:518–525.
   PubMed Web of Science ®Google Scholar
• SOLOMON KA, COVINGTON MB, DECICCO CP, NEWTON RC: The fate of pro-TNF-alpha following inhibition of metalloprotease-dependent processing to soluble TNF-alpha in human monocytes. J. Immunol. (1997) 159(9):4524–4531.
   PubMed Web of Science ®Google Scholar
• MULLBERG J, DURIE FH, OTTEN-EVANS C et al.: A metal-loprotease inhibitor blocks shedding of the IL-6 recep-tor and the p60 TNF receptor. J. Immunol. (1995) 155:5198–5205.
   PubMed Web of Science ®Google Scholar
• CROWE PD, WALTER BN, MOHLER KM et al.: A metallo-protease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J. Exp. Med. (1995) 181:1205–1210.
   PubMed Web of Science ®Google Scholar
• KIESSLING LL, GORDON EJ: Transforming the cell sur-face through proteolysis. Chem. Biol. (1998) 5:R49–R62.
   PubMed Web of Science ®Google Scholar
• PESCHON JJ, SLACK JL, REDDY P et al.: An essential role for ectodomain shedding in mamalian development. Science (1998) 282:1281–1284.
   PubMed Web of Science ®Google Scholar
• ••Study of the effects of TACE deficiency in cells and mice.
   Google Scholar
• WOJTOWICZ-PRAGA S, TORRI J, JOHNSON M etal. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with ad-vanced lung cancer. J. Gun. Oncol. (1998) 16(6) 2150–2156
   Google Scholar
• Bayer and Agouron compete in MMP inhibitor field. Scrip (3 July, 1998) 2349:20–21.
   Google Scholar
• BECKETT RP, WHITTAKER M: Matrix metalloproteinase inhibitors 1998. Exp. Opin. Ther. Patents (1998) 8(3)259–282.
   Google Scholar
• •Comprehensive overview of MMP inhibitors.
   Google Scholar
• WHITTAKER M, BROWN P: Recent advances in matrix metalloproteinase research and development. Curr. Opin. Drug Dis. Devel. (1998) 1(2):157–164.
   PubMedGoogle Scholar
• •Comprehensive overview of MMP inhibitors.
   Google Scholar
• BOTTOMLEY KM, JOHNSON WH, WALTER DS: Matrix metalloproteinase inhibitors in arthritis. J. Enzyme In-hibit. (1998) 13:79–101.
   PubMed Web of Science ®Google Scholar
• •Comprehensive overview of MMP inhibitors.
   Google Scholar
• WHITE AD, BOCAN TMA, BOXER PA et al: Emerging therapeutic advances for the development of second generation matrix metalloproteinase inhibitors. Curr. Pharm. Des. (1997) 3:45–58.
   Web of Science ®Google Scholar
• •Comprehensive overview of MMP inhibitors.
   Google Scholar
• ZASK A, LEVIN JI, KILLAR LM, SKOTNICKI JS: Inhibition of matrix metalloproteinase inhibitors: structure based design. Curr. Pharm. Des. (1996) 2:624–661.
   Web of Science ®Google Scholar
• •Comprehensive overview of MMP inhibitors.
   Google Scholar
• CASTELHANO AL, BILLEDEUA R, DEWDNEY N et al.: Novel indolactam-based inhibitors of matrix metallo-proteinases. Bioorg. Med. Chem. Lett. (1995) 5 (13) : 1415–1420.
   Web of Science ®Google Scholar
• BECHERER JD, MILLA M, ANDREWS R et al: Characteriza-tion of the TNFa converting enzyme. Inhibition of Ma-trix Metalloproteinases: therapeutic applications. New York Academy of Sciences Conference. Tampa, USA (1998). Ab-stract 39.
   Google Scholar
• PRATT LM, BECKETT P, BELLAMY CL et al.: The synthesis of novel matrix metalloproteinase inhibitors employ-ing the Ireland-Claisen Rearrangement. Bioorg. Med. Chem. Lett. (1998) 8:1359–1364.
   PubMed Web of Science ®Google Scholar
• XUE C-B, HE X, RODERICK J et al.: Design and synthesis of cyclic inhibitors of matrix metalloproteinases and TNF-a production. J. Med. Chem. (1998) 41:1745–1748.
   PubMed Web of Science ®Google Scholar
• MACPHERSON LJ, BAYBURT EK, CAPPARELLI MP et al:Discovery of CGS27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks carti-lage degradation in rabbits. J. Med. Chem. (1997) 40:2525–2532.
   PubMed Web of Science ®Google Scholar
• GONNELLA NC, LI Y-C, ZHANG X, PARIS GC: Bioactiveconformation of a potent stromelysin inhibitor deter-mined by x-nucleus filtered and multidimensional nmr spectrospcopy. Bioorg. Med. Chem. (1997) 5:2193–2201.
   PubMedGoogle Scholar